Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rigel jumps on RA data

RIGL gained $17.95 (224%) to $25.95 on Thursday after reporting

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE